Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 12-month Topline Safety Results

IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported the successful 12-month safety results of the Company’s “Mercury 1” Phase 3 registration trial for its fixed-dose combination product candidate, Roclatan™. Mercury 1 is a 12-month safety and efficacy tria

Vericred Announces Medicare Advantage Market Addition to Health Insurance Data Platform

Last month Vericred, a healthcare data services company, announced the addition of a provider-network notification capability to its suite of services, a first for the healthcare data industry. This week, Vericred took another important step to expand their offering with the addition of Medicare Advantage plan design and rate data, provider-network (Read more...)

New Exhaled Breath Sensor to Spot Diseases, Monitor Health

At KAIST, the Korea Advanced Institute of Science and Technology in South Korea, researchers have developed a new breath sensor that uses protein-encapsulated nanocatalysts to spot certain biomarkers of diseases. While the breath can hold a lot of information about what’s going on inside the body, the variety of gasses present and the la (Read more...)